### Sunday, September 24

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>OPENING KEYNOTE SESSION&lt;br&gt;Promenade East IV-VI&lt;br&gt;&lt;br&gt;&lt;strong&gt;Session Chairs: Cory Abate-Shen&lt;/strong&gt;, Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY, and &lt;strong&gt;Kevin M. Haigis&lt;/strong&gt;, Beth Israel Deaconess Medical Center, Boston, MA</td>
</tr>
<tr>
<td>6:00 p.m.-6:10 p.m.</td>
<td>Welcome Remarks&lt;br&gt;Cory Abate-Shen</td>
</tr>
<tr>
<td>6:10 p.m.-7:00 p.m.</td>
<td>Engineering the cancer genome&lt;br&gt;Tyler Jacks, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA</td>
</tr>
<tr>
<td>7:00 p.m.-7:50 p.m.</td>
<td>Unearthing mechanisms of malignant progression and resistance of cancer stem cells&lt;br&gt;Elaine Fuchs, The Rockefeller University, New York, NY</td>
</tr>
<tr>
<td>8:00 p.m.-10:00 p.m.</td>
<td>OPENING RECEPTION&lt;br&gt;Promenade West I-III</td>
</tr>
</tbody>
</table>

### Monday, September 25

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 a.m.-8:30 a.m.</td>
<td>CONTINENTAL BREAKFAST / NETWORKING ROUNDTABLES&lt;br&gt;Promenade Foyer and St. James Hall and Patio and Porte Cochere</td>
</tr>
<tr>
<td>8:30 a.m.-10:30 a.m.</td>
<td>PLENARY SESSION 1: TECHNOLOGICAL ADVANCES FOR MODELING CANCER IN MICE&lt;br&gt;Promenade East IV-VI&lt;br&gt;&lt;br&gt;&lt;strong&gt;Session Chair: Julien Sage&lt;/strong&gt;, Stanford University School of Medicine, Stanford, CA</td>
</tr>
<tr>
<td>8:30 a.m.-9:00 a.m.</td>
<td>Cancer modeling in the CRISPR age&lt;br&gt;Andrea Ventura, Memorial Sloan Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>9:00 a.m.-9:15 a.m.</td>
<td>Modeling colorectal cancer in vivo through CRISPR-based genome editing*&lt;br&gt;Lukas E. Dow, Weill Cornell Medical College, New York, NY</td>
</tr>
<tr>
<td>9:15 a.m.-9:45 a.m.</td>
<td>Quantitative and multiplex analysis of the genomic determinants of tumorigenesis&lt;br&gt;Monte Winslow, Stanford University School of Medicine, Stanford, CA</td>
</tr>
<tr>
<td>9:45 a.m.-10:00 a.m.</td>
<td>Capturing the integration of Ras-mutant cells into normal epithelial tissue using live imaging*&lt;br&gt;Cristiana M. Pineda, Yale University, New Haven, CT</td>
</tr>
<tr>
<td>10:00 a.m.-10:30 a.m.</td>
<td>Genetic dissection of cancer development, therapy response, and resistance in mouse models of breast cancer&lt;br&gt;Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands</td>
</tr>
</tbody>
</table>

*short talks from proffered abstracts
CONFERENCE PROGRAM

10:30 a.m.-11:00 a.m.  BREAK
Promenade Foyer

11:00 a.m.-1:00 p.m.  PLENARY SESSION 2:
ELUCIDATING CANCER MECHANISMS USING MOUSE MODELS
Promenade East IV-VI
Session Chair: Karen M. Cichowski, Brigham & Women's Hospital, Boston, MA

11:00 a.m.-11:30 a.m.  Driver mutations and cell-of-origin as critical factors determining the phenotypic characteristics of thoracic tumor subtypes
Anton J.M. Berns, Netherlands Cancer Institute, Amsterdam, The Netherlands

11:30 a.m.-11:45 a.m.  The tumor suppressor BAP1 regulates the Hippo pathway in pancreatic ductal adenocarcinoma*
Anwesha Dey, Genentech Inc., South San Francisco, CA

11:45 a.m.-12:15 p.m.  Deconstructing p53 pathways in tumor suppression
Laura D. Attardi, Stanford University School of Medicine, Stanford, CA

12:15 p.m.-12:30 p.m.  p120 catenin loss drives pancreatic cancer EMT and metastasis through activation of calcium signaling*
Jason R. Pitarresi, University of Pennsylvania, Philadelphia, PA

12:30 p.m.-1:00 p.m.  Somatic p53 mutations drive development of triple-negative breast cancer with evolutionarily distinct metastases
Guillermina Lozano, The University of Texas MD Anderson Cancer Center, Houston, TX

1:00 p.m.-1:15 p.m.  POSTER SESSION A HIGHLIGHTS
Promenade East IV-VI

(A01)  Somatic engineering of the mammary gland for the development of novel mouse models of triple-negative breast cancer
Stefano Annunziato, Netherlands Cancer Institute, Amsterdam, The Netherlands

(A02)  Potent synergism between FBXW7 and PI3K signaling in a mouse model of endometrial carcinogenesis
Ileana C. Cuevas, UT Southwestern Medical Center, Dallas, TX

(A03)  Perturbation of proteostasis is lethal in SMARCBI-deficient tumors
Giannicola Genovese, The University of Texas MD Anderson Cancer Center, Houston, TX

(A04)  Cross-species oncogenomics approach identifies PTPN11 as an oncogene and potential therapeutic target in melanoma
Minjung Kim, Moffitt Cancer Center, Tampa, FL

(A05)  Investigating mechanisms of obesity-mediated pancreatic cancer progression
Mandar Deepak Muzumdar, Koch Institute at MIT, Cambridge, MA

1:15 p.m.-3:30 p.m.  POSTER SESSION A / LUNCH
Promenade West I-III

*short talks from proffered abstracts
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 4:00 p.m.-6:00 p.m. | **PLENARY SESSION 3: MODELING THE TUMOR MICROENVIRONMENT**  
Promenade East IV-VI  
*Session Chair: Kwok-Kin Wong, New York University (NYU) Langone Medical Center, New York, NY* |
| 4:00 p.m.-4:30 p.m. | **Metabolic recycling in cancer**  
Marcia Haigis, Harvard Medical School, Boston, MA |
| 4:30 p.m.-4:45 p.m. | **Lineage specifiers SOX2 and NKX2-1 inversely regulate lung tumor immune microenvironment**  
Trudy G. Oliver, University of Utah, Salt Lake City, UT |
| 4:45 p.m.-5:15 p.m. | **Evaluation of the microenvironment in antitumor immune responses**  
Marcus W. Bosenberg, Yale University School of Medicine, New Haven, CT |
| 5:15 p.m.-5:30 p.m. | **Contribution of mutant microenvironment to hereditary cancer: Single-cell gene expression profiling of a genetically engineered mouse model of human hereditary BRCA1-related breast cancer**  
Carman M. Li, Harvard Medical School, Boston, MA |
| 5:30 p.m.-6:00 p.m. | **Tumor microenvironment: Stroma-tumor cell signaling defined by a cross-species approach**  
Gustavo W. Leone, Medical University of South Carolina Hollings Cancer Center, Charleston, SC |

**Tuesday, September 26**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 7:30 a.m.-8:30 a.m. | **CONTINENTAL BREAKFAST / NETWORKING ROUNDTABLES**  
Promenade Foyer and St. James Hall and Patio and Porte Cochere |
| 8:30 a.m.-10:30 a.m. | **PLENARY SESSION 4: STEM CELLS AND DEVELOPMENTAL PATHWAYS IN CANCER**  
Promenade East IV-VI  
*Session Chair: Michael M. Shen, Columbia University College of Physicians & Surgeons, New York, NY* |
| 8:30 a.m.-9:00 a.m. | **Intra- and intertumoral heterogeneity and response to therapy in mouse models of SCLC**  
Julien Sage, Stanford University School of Medicine, Stanford, CA |
| 9:00 a.m.-9:15 a.m. | **Elucidating mechanisms of p53-deficient breast cancer development via lineage tracing and clonal analysis**  
Zhe Li, Brigham & Women’s Hospital and Harvard Medical School, Boston, MA |
| 9:15 a.m.-9:45 a.m. | **Imaging stem cell signals in cancer heterogeneity and therapy resistance**  
Tannishtha Reya, University of California San Diego, La Jolla, CA |

*short talks from proffered abstracts*
10:45 a.m.-11:00 a.m. 
*short talks from proffered abstracts

11:00 a.m.-11:30 a.m. 
Normal and cancer stem cells in multistage carcinogenesis
Allan Balmain, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

11:30 a.m.-11:45 a.m. 
Clonal dynamics during breast cancer dormancy and recurrence*
James V. Alvarez, Duke University, Durham, NC

11:45 a.m.-12:15 p.m. 
RNA sequencing–based analysis of transposon-induced tumors reveals novel insights into disease pathogenesis*
David A. Largaespada, University of Minnesota, Minneapolis, MN

12:15 p.m.-12:30 p.m. 
RNA sequencing–based analysis of transposon-induced tumors reveals novel insights into disease pathogenesis*
David A. Largaespada, University of Minnesota, Minneapolis, MN

12:30 p.m.-1:00 p.m. 
Of mice and men: Using systems biology approaches to study human cancer
Cory Abate-Shen, Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY

1:00 p.m.-2:30 p.m. 
LUNCH ON OWN

2:30 p.m.-4:15 p.m. 
PLENARY SESSION 6: BEYOND GENETICALLY ENGINEERED MOUSE MODELS
Promenade East IV-VI
Session Chair: Guillermina Lozano, The University of Texas MD Anderson Cancer Center, Houston, TX

2:30 p.m.-3:00 p.m. 
GEMMs and GEOs to characterize pancreatic cancer initiation and progression
David A. Tuveson, Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, NY

3:00 p.m.-3:30 p.m. 
Organoid models of bladder cancer
Michael M. Shen, Columbia University College of Physicians & Surgeons, New York, NY

3:30 p.m.-3:45 p.m. 
Investigating lung cancer cells-of-origin using three-dimensional organoid cultures*
Christine Fillmore Brainson, University of Kentucky, Lexington, KY

3:45 p.m.-4:15 p.m. 
The tumor immune landscape and heterogeneity projects
Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Boston, MA

*short talks from proffered abstracts
4:15 p.m.-4:45 p.m.  
**BREAK**  
Promenade Foyer

4:45 p.m.-5:40 p.m.  
**KEYNOTE ADDRESS**  
Promenade East IV-VI  
*Session Chair: Katerina A. Politi, Yale Cancer Center, New Haven, CT*  
*Interrogating cancer drivers and dependencies using non-germline mouse models*  
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, NY

5:40 p.m.-5:55 p.m.  
**POSTER SESSION B HIGHLIGHTS**  
Promenade East IV-VII  
(B01)  
A genetically engineered mouse model of de novo bone metastasis  
Juan Martin Arriaga, Columbia University Medical Center, New York, NY

(B02)  
Neutrophils and Snail orchestrate the establishment of a pro-tumor microenvironment in lung adenocarcinoma  
Etienne Meylan, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

(B03)  
Acinar cell expansion: A new step in pancreatic tumorigenesis  
Patrick Neuhoefer, Stanford University, Stanford, CA

(B04)  
Activating K-RasA146T mutations induce Mapk-dependent hyperproliferation in the intestinal epithelium  
Emily Poulin, Beth Israel Deaconess Medical Center, Boston, MA

(B05)  
BRAF inhibition and cytokine therapy for melanoma: A novel rational combined approach  
Gabriele Romano, The University of Texas MD Anderson Cancer Center, Houston, TX

(B06)  
A SOX9 bile duct progenitor as a cell of origin of hepatocellular carcinoma  
Patrick Viator, Children's Hospital of Philadelphia, Philadelphia, PA

6:00 p.m.-8:30 p.m.  
**POSTER SESSION B/RECEPTION**  
Promenade West I-III

Wednesday, September 27

7:30 a.m.-8:15 a.m.  
**CONTINENTAL BREAKFAST / NETWORKING ROUNDTABLES**  
Promenade Foyer and St. James Hall and Patio and Porte Cochere

8:15 a.m.-9:45 a.m.  
**PLENARY SESSION 7: TARGETING THE TUMOR MICROENVIRONMENT**  
Promenade East IV-VI  
*Session Chair: Martin McMahon, University of Utah Huntsman Cancer Institute, Salt Lake City, UT*
8:15 a.m.-8:30 a.m.  
**Lung cancer mouse models for preclinical testing of novel and immune therapies**  
Kwok-Kin Wong, New York University (NYU) Langone Medical Center, New York, NY

8:30 a.m.-9:00 a.m.  
**The immune microenvironment in lung cancer: Lessons from mouse models**  
Katerina A. Politi, Yale Cancer Center, New Haven, CT

9:00 a.m.-9:30 a.m.  
**Targeting the drug- and immune-privileged sanctuary of pancreas cancer**  
Sunil R. Hingorani, Fred Hutchinson Cancer Research Center, Seattle, WA

9:30 a.m.-9:45 a.m.  
**Selective lethality of cisplatin in pancreatic cancer is dependent on mitotic functions of BRCA2**  
Kenneth P. Olive, Columbia University Medical Center, New York, NY

9:45 a.m.-10:15 a.m.  
**BREAK**  
Promenade Foyer

10:15 a.m.-12:15 p.m.  
**PLENARY SESSION 8:**  
**USING MOUSE MODELS TO STUDY DRUG RESISTANCE**  
Promenade East IV-VI  
**Session Chair:** Marcus W. Bosenberg, Yale University School of Medicine, New Haven, CT

10:15 a.m.-10:45 a.m.  
**Using mouse models to improve cancer therapy**  
Michael T. Hemann, David H. Koch Institute for Integrative Cancer Research at MIT, Boston, MA

10:45 a.m.-11:15 a.m.  
**In vivo screens assessing drug response and resistance in acute leukemias characterized by hyperactive Ras signaling**  
Kevin M. Shannon, University of California San Francisco, San Francisco, CA

11:15 a.m.-11:45 a.m.  
**Mutational activation of PI3-kinase-α promotes dedifferentiation of BRAFV600E-driven lung tumor cells**  
Martin McMahon, University of Utah Huntsman Cancer Institute, Salt Lake City, UT

11:45 a.m.-12:15 p.m.  
**Using mouse models to develop therapies for Ras-driven cancers**  
Karen M. Cichowski, Brigham & Women’s Hospital, Boston, MA

12:15 p.m.-1:00 p.m.  
**MEETING SUMMARY**  
Promenade East IV-VI  
**Closing Remarks**  
Julien Sage, Stanford University School of Medicine, Stanford, CA

1:00 p.m.  
**DEPARTURE**